Bupropion Sustained Release for Treatment of Tobacco Dependence

Hays, J. Taylor; Ebbert, Jon O.
August 2003
Mayo Clinic Proceedings;Aug2003, Vol. 78 Issue 8, p1020
Academic Journal
Discusses evidence of efficacy and common adverse effects of bupropion sustained release (SR) and the clinical characteristics of patients at higher risk for adverse effects when bupropion SR is prescribed for treatment of tobacco use and dependence. Reducing risk of serious adverse effects linked with bupropion SR by careful selection of patients; Bupropion SR for postabstinence weight gain; Death and seizures; Treatment-emergent hypertension; Clinical approach to limit adverse effects.


Related Articles

  • Varenicline more efficacious for smoking cessation.  // Geriatrics;Sep2006, Vol. 61 Issue 9, p7 

    The article discusses research being done on the effectiveness of varenicline in smoking cessation. It references a study published in the 2006 issue of "Journal of the American Medical Association." The methodology of the study is described. The most common side effects associated with...

  • Bupropion (Zyban, Wellbutrin SR): reports of deaths, seizures, serum sickness. Wooltorton, Eric // CMAJ: Canadian Medical Association Journal;1/8/2002, Vol. 166 Issue 1, p68 

    Focuses on suspected adverse drug reactions for bupropion, including reports of a number of deaths, seizures or convulsions, and serum-sickness-like reactions. How the drug appears to block noradrenergic reuptake and dopaminergic reuptake in the brain, and is used as an antidepressant and...

  • Chantix and neuropsychiatric side effects. Elliott, William T. // Primary Care Reports;Dec2011 Pharmacology Watch, p2 

    The article presents the findings of two epidemiologic studies sponsored by the U.S. Food and Drug Administration (FDA) in 2011 which showed no difference in the risk of neuropsychiatric hospitalization between smoking cessation drug varenicline (Chantix) and nicotine replacement therapy.

  • VARENICLINE.  // Complete Guide to Prescription & Nonprescription Drugs 2012;2012, p830 

    The article presents information on varenicline, an antismoking agent, including its dosage, usage, adverse reactions, side effects, precautions when administering, and possible interaction with other drugs.

  • Bupropion.  // Reactions Weekly;1/24/2009, Issue 1236, p11 

    The article describes the case of a 34-year-old man who acquired rhabdomyolysis. The patient developed the said condition while undergoing treatment with bupropion as part of his smoking cessation therapy. He was asked to stop bupropion therapy and continued to use transdermal nicotine patch...

  • Bupropion (Zyban, sustained-release tablets): update. Dunlop, Heather // CMAJ: Canadian Medical Association Journal;1/11/2000, Vol. 162 Issue 1, p106 

    Reports adverse drug reactions (ADRs) to bupropion (Zyban, sustained-release tablets), which is used for smoking cessation. Number and type of reactions to Zyban as reported to the Canadian Adverse Drug Reaction Monitoring Program; ADRs, including central and peripheral nervous system,...

  • COMMENTARY: Review: Clonidine is more effective than placebo for long-term smoking cessation but has side effects. Bentz, Charles J. // ACP Journal Club;Jan/Feb2005, Vol. 142 Issue 1, p12 

    The article reports that clonidine is more effective than placebo for long-term smoking cessation but has side effects. The systematic review supports the conclusions of the U.S. Public Health Service clinical guideline on treating tobacco use and dependence. Clinicians should now have...

  • creating a healthier life. Rouse, Debra // Better Nutrition;Apr2007, Vol. 69 Issue 4, p46 

    The article discusses how to quit smoking through natural therapy. According to the author, addiction to nicotine is very difficult to overcome, because smoking is a physical and behavioral compulsion. Drugs have a low success rate, and also have side effects. In natural methods, the behaviors...

  • Nicotine conjugate vaccines: A novel approach in smoking cessation. Kitchens, Caroline M.; Foster, Stephan L. // Journal of the American Pharmacists Association: JAPhA;Jan/Feb2012, Vol. 52 Issue 1, p116 

    The article discusses pharmacologic therapeutic options for smoking cessation in the U.S. These options are direct nicotine replacement therapy (NRT), anti-depressant medications and a nicotine receptor partial agonist. Dosage forms of NRT include chewing gums, lozenges, patches, nasal sprays...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics